ERn Financial LLC Buys 62 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

ERn Financial LLC boosted its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.6% during the fourth quarter, Holdings Channel.com reports. The fund owned 1,790 shares of the medical research company’s stock after acquiring an additional 62 shares during the period. ERn Financial LLC’s holdings in Thermo Fisher Scientific were worth $975,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its stake in Thermo Fisher Scientific by 0.6% during the 3rd quarter. Vanguard Group Inc. now owns 32,760,738 shares of the medical research company’s stock worth $16,582,503,000 after acquiring an additional 180,618 shares during the period. State Street Corp increased its stake in shares of Thermo Fisher Scientific by 0.3% in the 2nd quarter. State Street Corp now owns 16,116,956 shares of the medical research company’s stock valued at $8,414,693,000 after purchasing an additional 55,458 shares during the last quarter. Morgan Stanley increased its stake in shares of Thermo Fisher Scientific by 0.4% in the 3rd quarter. Morgan Stanley now owns 12,418,429 shares of the medical research company’s stock valued at $6,285,838,000 after purchasing an additional 50,736 shares during the last quarter. Moneta Group Investment Advisors LLC increased its stake in shares of Thermo Fisher Scientific by 104,536.8% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 8,355,245 shares of the medical research company’s stock valued at $4,601,150,000 after purchasing an additional 8,347,260 shares during the last quarter. Finally, Providence Capital Advisors LLC increased its stake in shares of Thermo Fisher Scientific by 61,754.7% in the 1st quarter. Providence Capital Advisors LLC now owns 5,842,175 shares of the medical research company’s stock valued at $10,136,000 after purchasing an additional 5,832,730 shares during the last quarter. Institutional investors own 89.23% of the company’s stock.

Insider Activity

In other news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $555.63, for a total value of $5,556,300.00. Following the transaction, the chief executive officer now directly owns 49,155 shares of the company’s stock, valued at approximately $27,311,992.65. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, SVP Michael A. Boxer sold 14,566 shares of the business’s stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total value of $8,186,092.00. Following the completion of the sale, the senior vice president now directly owns 12,901 shares of the company’s stock, valued at approximately $7,250,362. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $555.63, for a total value of $5,556,300.00. Following the completion of the sale, the chief executive officer now directly owns 49,155 shares of the company’s stock, valued at $27,311,992.65. The disclosure for this sale can be found here. Insiders have sold 50,277 shares of company stock valued at $28,513,384 in the last ninety days. 0.32% of the stock is owned by company insiders.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. TheStreet upgraded Thermo Fisher Scientific from a “c+” rating to a “b-” rating in a research note on Friday, December 22nd. Sanford C. Bernstein reiterated a “market perform” rating on shares of Thermo Fisher Scientific in a research note on Monday, January 8th. Royal Bank of Canada lifted their price target on Thermo Fisher Scientific from $592.00 to $642.00 and gave the company an “outperform” rating in a research note on Thursday, February 1st. Barclays downgraded Thermo Fisher Scientific from an “overweight” rating to an “equal weight” rating and raised their price objective for the company from $475.00 to $555.00 in a report on Wednesday, January 24th. Finally, Wolfe Research assumed coverage on Thermo Fisher Scientific in a report on Wednesday, December 13th. They set an “outperform” rating and a $575.00 price objective on the stock. Five investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $599.00.

Thermo Fisher Scientific Trading Up 0.3 %

TMO traded up $1.84 during midday trading on Friday, hitting $581.21. 1,081,545 shares of the company were exchanged, compared to its average volume of 1,473,417. The firm has a market capitalization of $221.62 billion, a P/E ratio of 37.62, a P/E/G ratio of 2.43 and a beta of 0.80. Thermo Fisher Scientific Inc. has a 1-year low of $415.60 and a 1-year high of $603.82. The firm’s 50 day moving average price is $565.87 and its 200-day moving average price is $520.64. The company has a quick ratio of 1.39, a current ratio of 1.75 and a debt-to-equity ratio of 0.67.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, January 31st. The medical research company reported $5.67 EPS for the quarter, topping the consensus estimate of $5.64 by $0.03. The firm had revenue of $10.89 billion for the quarter, compared to the consensus estimate of $10.73 billion. Thermo Fisher Scientific had a return on equity of 18.78% and a net margin of 13.99%. The business’s quarterly revenue was down 4.9% compared to the same quarter last year. During the same period in the previous year, the business earned $5.40 EPS. As a group, equities analysts forecast that Thermo Fisher Scientific Inc. will post 21.52 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, April 15th. Stockholders of record on Friday, March 15th will be paid a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.27%. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. The ex-dividend date is Thursday, March 14th. Thermo Fisher Scientific’s payout ratio is currently 10.10%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.